CPE raises concern on availability and pricing issues of Atorvastatin tablets


Share post:

The Community Pharmacy England has raised a concern on pricing and availability of Atorvastatin tablets.

CPE is In discussions with the Department of Health and Social Care (DHSC) and have warned about the serious impact this issue is now having on pharmacies.

The issue was highlighted after a number of pharmacy owners have got in touch with CPE about the pricing and availability of Atorvastatin tablets.

The association said: “The DHSC Supply Team has been working closely with manufacturers and wholesalers on this issue.

Thank you to those of you who have taken the time to report the increased prices that you have purchased at.

We will continue to use these reports to highlight just how much of an impact this is having on pharmacies who are desperately trying to get hold of limited stock and having to pay inflated prices for it without any certainty of their final reimbursement prices.”


Please enter your comment!
Please enter your name here

Current Issue June 2023

Related articles

MHRA grants authorisation for LEO Pharma’s Adtralza 2 mL pen solution

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution...

Grundon launches maiden UK-wide inhaler recycling programme

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and...

‘Record fine imposed on hydrocortisone manufacturers for dominant position abuse and 10,000% price increase’

The Competition Appeal Tribunal (CAT) has upheld the Competition and Markets Authority’s (CMA) findings against two pharmaceutical manufacturers...

Vision Report: Legal reforms, adequate funding imperative for success of community pharmacy

Achieving the community pharmacy vision necessitates legal adjustments and additional funding beyond recent boosts, the pharmacy vision document...